Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VYF
|
|||
| Former ID |
DIB002702
|
|||
| Drug Name |
RDEN1delta30
|
|||
| Synonyms |
RDEN4delta30; Dengue virus vaccine, NIH; Flavivirus vaccine, NIH; Live attenuated dengue virus vaccine, NIH; RDEN4delta30-4995; Recombinant dengue virus vaccine, NIH; TetraVax-DV; Dengue virus vaccine (attenuated chimeric), NIH; RDEN2/4Delta30(ME); RDEN3-3'D4delta30; RDEN3/4delta30(ME); RDEN4delta30-200,201
Click to Show/Hide
|
|||
| Indication | Dengue fever [ICD-11: 1D2Z; ICD-10: A97, A97.9; ICD-9: 61] | Phase 2 | [1] | |
| Company |
Sanofi pasteur; glaxosmithkline; walter reed army institute of research; naval medical research center; army medical research and materiel command
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01696422) Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.